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Establishment and maintenance of CNS glial cell
identity ensures proper brain development and func-
tion, yet the epigenetic mechanisms underlying glial
fate control remain poorly understood. Here, we
show that the histone deacetylase Hdac3 controls
oligodendrocyte-specificationgeneOlig2expression
and functions as a molecular switch for oligodendro-
cyte and astrocyte lineage determination. Hdac3
ablation leads to a significant increase of astrocytes
with aconcomitant loss of oligodendrocytes. Lineage
tracing indicates that the ectopic astrocytes originate
fromoligodendrocyte progenitors. Genome-wide oc-
cupancy analysis reveals that Hdac3 interacts with
p300 to activate oligodendroglial lineage-specific
genes, while suppressing astroglial differentiation
genes including NFIA. Furthermore, we find that
Hdac3 modulates the acetylation state of Stat3 and
competes with Stat3 for p300 binding to antagonize
astrogliogenesis. Thus, our data suggest that Hdac3
cooperates with p300 to prime and maintain oligo-
dendrocyte identity while inhibiting NFIA and Stat3-
mediated astrogliogenesis, and thereby regulates
phenotypic commitment at the point of oligodendro-
cyte-astrocytic fate decision.
INTRODUCTION
Oligodendrocytes (OLs) and astrocytes, the major glial subtypes
in the CNS, play key roles in brain development and homeo-
static maintenance. They are derived developmentally from
neural stem cells that give rise to transit-amplifying intermediate316 Developmental Cell 36, 316–330, February 8, 2016 ª2016 Elseviprogenitors. However, the mechanisms that dictate OL and
astrocyte fate choice, and the extent of phenotypic plasticity
within these glial lineages, remain poorly understood.
OL precursors (OPCs) are specified from neural progenitors
through intermediate primitive OL progenitors (designated as
pri-OPC) expressing Olig1 and Olig2 (Lu et al., 2002; Zhou and
Anderson, 2002), which precede the expression of the OPC
markers PDGFRa and NG2. OL lineage commitment is critical
for subsequent differentiation and axonal myelination. OL pro-
genitors have been shown to exhibit multilineage competence,
and can adopt an alternative fate, such as type II astrocytes, un-
der certain environmental and genetic conditions, both in vitro
and in vivo (Kondo and Raff, 2000; Nunes et al., 2003; Raff
et al., 1983; Zhu et al., 2012). Nonetheless, the molecules that
control the fate choice of OL progenitors andmaintain their iden-
tity have not yet been fully defined. Activation of the Janus kinase
(Jak)-Stat pathway and BMP-Smad signaling promotes expres-
sion of astrocytic genes such as glial fibrillary acidic protein
(GFAP), as well as astrogliogenesis from neural progenitors or
OPCs in culture (He et al., 2005; Nakashima et al., 1999). The
balance of OL- and astrocyte-promoting cues has been pro-
posed to determine lineage specification and progression (Glas-
gow et al., 2014; He and Lu, 2013; Zuchero and Barres, 2013).
A series of transcriptional regulators have been identified to
regulate OL development (Emery, 2010; He and Lu, 2013; Zu-
chero and Barres, 2013). For instance, Olig2 is a key regulator
of OL lineage specification and differentiation (Lu et al., 2002;
Takebayashi et al., 2002; Zhou and Anderson, 2002). It can direct
Smarca4/Brg1-mediated SWI/SNF chromatin remodeling com-
plex to the enhancers of OL lineage genes to initiate OPC dif-
ferentiation (Yu et al., 2013). In addition, Olig2 also represses
expression of GFAP, and regulates the developmental plasticity
of NG2+ OL precursors in developing brain (Cai et al., 2007;
Nakashima et al., 1999; Zhu et al., 2012). Although signaling
pathways such as Sonic hedgehog and fibroblast growth factor
(Gabay et al., 2003; Lu et al., 2000) have been shown to regulateer Inc.
Olig2 expression, the transcriptional and epigenetic events that
directly target and activate Olig2 to establish the OL progenitor
state are not fully understood.
The histone modifiers, histone acetyltransferases (HATs) and
histone deacetylases (HDACs), shape chromatin conformations
to control gene transcription during development (Haberland
et al., 2009b; Yu et al., 2010). pan-HDAC inhibitors have been
shown to block OPC differentiation in vitro (Marin-Husstege
et al., 2002). Recent studies suggest a critical role for class I
HDACs in OL development and regeneration in vivo (Shen
et al., 2008; Ye et al., 2009). However, to date the individual
HDAC-mediated epigenetic machinery in the control of glial
fate choice and lineage identity has not been fully defined.
The existence of different class I HDAC complexes raises the
question of potential specificity in their enzymatic activities and
biological functions. In a screen of the effect of specific HDAC in-
hibitors on OPC differentiation, we found that Hdac3 inhibitors
strongly suppress expression of the key OL specification gene
Olig2, compared with other HDAC inhibitors. Although structur-
ally similar among class I HDAC, Hdac3 exerts distinct functions
by forming a stable enzymatic complex with its co-factor NCoR1
or NCoR2/SMRT (silencing mediator of retinoic and thyroid re-
ceptors), in contrast to Hdac1/2, which primarily form complexes
with Sin3, NuRD, or CoREST in mammalian cells (Haberland
et al., 2009b).
Here, we show that Hdac3 directly targets and activates Olig2
expression to control OL-astrocyte fate decision. Cell-type and
temporally specific fate-mapping studies indicate that Hdac3
deletion causes a conversion of OL progenitors into astrocytes,
with attendant oligodendrocytic loss and myelination defects.
In addition, we find that Hdac3 sets a stage for OL lineage
commitment through coordinating with a chromatin remodeler
p300 acetyltransferase while antagonizing Stat3 activity through
modulating its acetylation state to inhibit astrogliogenesis. Our
genome-wide occupancy study at different stages further offers
a global view of gene expression programs regulated by Hdac3
during OL development, and provides insights into key mecha-
nisms that may underpin cellular plasticity and fate choice be-
tween glial subtypes in the CNS.
RESULTS
Hdac3 Regulates Olig2 Expression and Is Highly
Enriched in the OL Lineage
To determine the effects of specific HDAC inhibition on expres-
sion of the OL specification factor Olig2, we treated OPCs iso-
lated from postnatal day 2 (P2) rat brains with inhibitors specific
to Hdac1, Hdac3, and Hdac8. Treatment with Hdac1 or Hdac8
inhibitors (Hdac1i or Hdac8i) exerts minimal effects on Olig2
expression. However, the Hdac3 inhibitor RGFP966 or apicidin
(Malvaez et al., 2013; Wells et al., 2013), which targets the
Hdac3 and NCoR complex, strongly suppressed Olig2 expres-
sion assayed by immunocytochemistry, qRT-PCR, and western
blot analyses (Figures 1A–1C). This suggests that targeted inhi-
bition of Hdac3 activity blocks Olig2 expression.
Hdac3 was detected in PDGFRa+ OPCs and mature MBP+
(myelin basic protein) OLs (Figures 1D and 1E), as well as
Olig2-expressing OLs in culture (Figure 1F). In the corpus cal-
losum and spinal white matter at P14, strong Hdac3 nuclearDeveloplabeling was observed in CC1+ differentiating OLs (Figures 1G
and 1H), in contrast to a weak labeling in PDGFRa+ OPCs. The
proportions of CC1+ and PDGFRa+ cells among the Hdac3+ cells
in the spinal white matter were approximately 85.2% ± 5.8% and
6.0% ± 3.5%, respectively (>800 cell count; n = 3 animals; Fig-
ure 1I). Hdac3 exhibited a weak expression in a population of as-
trocytes in the corpus callosum marked by GFAP-GFP signals
(Zhuo et al., 1997) (Figure 1J), in contrast to the intense Hdac3
signals in OLs (Figures 1J and S1B) and neurons (Figure S1A).
Similarly, Hdac3 is expressed weakly or is absent in astrocytes
marked by aldolase C and glutamine synthetase (GS) (Figures
S1C and S1D). qRT-PCR analysis indicated that Hdac3 expres-
sion level was elevated as OPCs became differentiated and
OLs matured (Figure 1K), suggesting that Hdac3 expression in-
creases during OL lineage progression.
Hdac3 Mutants Have Fewer OLs and OPCs, Exhibiting
Myelination Defects
To assess the role of Hdac3 in OL development in vivo, we
deleted Hdac3 floxed alleles in mice by crossing Hdac3lox/lox
mice with an OL lineage-expressing Olig1-Cre line (Xin et al.,
2005; Ye et al., 2009) (Figure 2A). The resulting mutant
Hdac3lox/lox;Olig1Cre+/ mice (referred to as CKO-Olig1) were
born at a normal Mendelian ratio and survived to adulthood.
We observed that CKO-Olig1 mice but not their control
Hdac3lox/+;Olig1Cre+/ littermates developed tremors from post-
natal week 3 and abnormal limb clasping (Figure 2B), typical
manifestations of widespread myelination defects in mice. The
optic nerve, a myelinated white matter tract, from CKO-Olig1
mice was translucent (Figure 2C), indicating a severe deficiency
in myelin formation in the CNS.
To characterize the myelin-deficient phenotype, we examined
myelin gene expression in CKO-Olig1 mice. Immunostaining
confirmed that Hdac3 expression was essentially eliminated in
the corpus callosum of CKO-Olig1 mice (Figure 2D). At P21, in
contrast to robust expression of myelin genes such as Mbp
and Plp1 (proteolipid protein 1) in control mice, Mbp and Plp1
was substantially reduced in the cortex and spinal cord of
Hdac3mutants (Figures 2E and 2F). Similarly, fluorescent inten-
sity of MBP was also diminished in the CKO-Olig1 mutants
(Figure 2G).
In light of the substantial reduction of myelin genes, we further
examined myelin sheath assembly in the CNS of these mutants
by electron microscopy. In contrast to the large number of
myelinated axons in control mice at P14 (Figure 2H), the percent-
age of myelinated axons was greatly reduced in the optic nerve
of CKO-Olig1 mutants (Figures 2H and 2J). Strikingly, by P62,
myelinated axons were essentially undetectable in the Hdac3-
mutant optic nerves (Figure 2I), raising the possibility that
Hdac3 is required for myelin maintenance in the adult stage
in addition to its role in OL differentiation. Myelinated axons
were present in the spinal cord of Hdac3 mutants; however,
the thickness of myelin sheaths was substantially reduced in
the postnatal stage and adulthood (Figures S2A–S2D). These
observations indicate that Hdac3 is required for OL myelination,
and exhibits a region-selective function in myelinogenesis in
the CNS.
We next investigated whether alterations of OPC development
contribute to myelination defects. In the brain of CKO-Olig1mental Cell 36, 316–330, February 8, 2016 ª2016 Elsevier Inc. 317
Figure 1. Hdac3 Regulates Olig2 Expression and Is Expressed in the OL Lineage
(A) Olig2 immunostaining in OPCs treated with DMSO, Hdac1i (2.5 mM), Hdac8i (5 mM), RGFP966 (10 mM), or apicidin (100 nM) and counterstained with DAPI.
(B and C) Olig2 expression in OPCs treated with different HDAC inhibitors over vehicle assayed by qRT-PCR (B) or western blotting (C). Experiments were
performed three times for each treatment. ***p < 0.001; ANOVA with Newman-Keuls test.
(D–F) Primary rat OPCs (D) and differentiated OLs (OL) (E, F) were immunostained for Hdac3, PDGFRa, MBP, and Olig2. Arrows indicate co-labeling cells.
(G–I) immunostaining of Hdac3, CC1, and PDGFRa on the corpus callosum (G) and spinal white matter region (H) in wild-type mice at P14. Arrows and
arrowheads indicate Hdac3 cells co-labeling with CC1 and PDGFRa, respectively. (I) shows the percentage of CC1- or PDGFRa-positive cells among Hdac3+
cells (n = 3 animals, > 600 cell counts).
(J) Co-immunolabeling of GFAP-GFPwith Hdac3 andCC1 in the corpus callosum at P14. Arrows and arrowheads indicate Hdac3+ cells co-labelled with CC1 and
GFP, respectively.
(K) qRT-PCR analysis of Hdac3 expression in rat OPCs and differentiating OLs (OL) with T3 treatment for 24 hr (iOL) and 72 hr (mOL).
Scale bars represent 50 mm (A), 25 mm (D–F), and 50 mm (G, H, J).
See also Figure S1.mutants at P14, PDGFRa mRNAs were detectable, although
their number was significantly reduced in the cortex and corpus
callosum (Figures 2K and 2O). Similarly, Olig2+ cells were
also diminished in the cortex (Figures 2L and 2O). To address
the question of whether the presumptive OPCs were maintained
but without OPCmarker expression, we then bred PDGFRa pro-
moter-driven H2bGFP reporter (PDGFRa-H2bGFP) (Hamilton
et al., 2003) into the CKO-Olig1 mutants, and observed that
the number of PDGFRa-H2bGFP+ cells decreased in the mu-318 Developmental Cell 36, 316–330, February 8, 2016 ª2016 Elsevitants, suggesting a reduction of PDGFRa+ OPCs in the absence
of Hdac3 (Figure 2M).
Despite the reduction in number in the Hdac3 mutants,
OPCs were able to proliferate as assayed by bromodeoxyuridine
(BrdU) incorporation, though toa lesser extent comparedwith the
control at P14 (Figures 2N and 2P). Proliferating BrdU+/PDGFRa+
cellsweremainly detected asOPCswith less complexprocesses
(Figure 2N), compared with non-mitotic BrdU/PDGFRa+ cells,
which had extended cellular processes (Figure 2N, arrowhead).er Inc.
Figure 2. Hdac3 Ablation Leads to OL Loss and Myelination Deficits
(A) Cre-mediated excision of floxed Hdac3 exons encoding the nuclear import sequence and a carboxy-terminal region that confers transcriptional activity.
(B) Tail suspension test for control (Olig1Cre+/;Hdac3lox/+) and CKO-Olig1 (Olig1Cre+/;Hdac3lox/lox) mice at P60. Mutant mice developed abnormal limb clasps.
(C) Appearance of the optic nerves of control and CKO-Olig1 mice at P21.
(D) Immunostaining of Hdac3 in the corpus callosum of control and CKO-Olig1 mice at P21.
(E–G) Mbp and Plp1 mRNAs or MBP immunostaining on the brain (E, G) and spinal cord (F) from control and CKO-Olig1 mice at P21.
(H–J) Electron microscopy of optic nerves from control and CKO-Olig1 mice at P14 and P62. (J) shows the percentage of myelinated axons. n = 3 animals.
(K and L) Expression of PDGFRa and Olig2 in the control and CKO-Olig1 brain at P14.
(M) GFP signals in the P14 control and CKO-Olig1 brain carrying a PDGFRa-GFP reporter.
(N) PDGFRa and BrdU labeling in cortices of control and CKO-Olig1 mice after 2 hr of pulse-labeling at P14. Arrow and arrowhead indicate co-labeling cells.
(O and P) Histograms depict the relative percentage of Olig2+ or PDGFRa+ (O), or BrdU+ cells among PDGFRa+ OPCs (P). n = 3 animals, > 600 cell counts.
*p < 0.05, Student’s t test.
Scale bars represent 100 mm (D, E–G), 1 mm (H, I), 100 mm (K, L), and 50 mm (M, N).
See also Figure S2.Similarly, a population of residual OPCs exhibited complex
extended processes as shown by NG2+ immunostaining (Fig-
ure S2E). A fewNG2+ cells displayed extended processes, which
appeared to fill OL void space or make contacts with crossing
axon fibers (Figure S2E). The NG2+ cells were co-labeled withDevelopPDGFRa but not GFAP (Figures S2F and S2G), indicating that
they were OPCs or immature OLs, not astrocyte-like cells.
Together, theseobservations suggest thatHdac3deletion results
in a loss of OLs and their progenitors, and blocks the differentia-
tion of remaining OPCs at a pre-myelinating stage.mental Cell 36, 316–330, February 8, 2016 ª2016 Elsevier Inc. 319
Deletion ofHdac3 Leads to Ectopic Astrocyte Formation
The reduction of OPCs in Hdac3 deletion in Olig1+ progenitors
could be due to the death of OPCs or the adoption of an alterna-
tive cell fate. We did not detect any significant cell death in
mutant brains assayed by the active form of caspase-3 (Fig-
ure S3A). To examine whether deletion of Hdac3 affects other
cell types in the CNS, we analyzed the expression of neuronal
and astrocyte-specific markers in CKO-Olig1mice. No substan-
tial alterations of cortical neuron formation or lamination were
observed, as marked by the pan-neuronal marker NeuN (Fig-
ure S3B). In control mice, expression of the astrocyte markers
GFAP andGlastwas barely detectable in the cortical gray matter
postnatally or in adulthood (Figures 3A and 3B). In contrast,
drastic upregulation of GFAP and Glast was observed in the
developing cortex of CKO-Olig1 mice at the perinatal stage,
and GFAP+ cells persist throughout adulthood (Figures 3A and
3B). Consistently, western blot analysis indicated that GFAP
protein levels were upregulated in the Hdac3 mutant cortex,
whereas MBP expression was diminished, suggesting a recip-
rocal relationship of GFAP and MBP expression (Figure 3C).
To determine whether the number of astrocytes was altered in
the mutants, we examined the expression of GS, an astrocyte
marker independent of GFAP expression (Cai et al., 2007), and
detected that the density of GS+ astrocytes in the cortex of
Hdac3 mutants significantly increased relative to control mice
at perinatal stages and adulthood (Figures 3D and 3E). A recent
study indicates that Sox10 and nuclear factor IA (NFIA) antago-
nize each other to modulate OL and astrocyte subtype differen-
tiation in the spinal cord (Glasgow et al., 2014). Consistently, we
observed a reduction of Sox10+ OLs alongside an increase of
NFIA+ astrocytes in the corpus callosum of CKO-Olig1 mutants
(Figures 3F–3H). To determine whether the increase of ectopic
astrocytes could be due to astrocyte proliferation, we then car-
ried out co-immunostaining of GFAPwith the proliferativemarker
Ki67 at P14. Essentially no Ki67 expression was detected in the
GFAP+ cells, suggesting very little, if any, proliferation of GFAP+
astrocytes in Hdac3 mutants (Figure 3I).
It is possible that Hdac3 deletion might perturb neuronal for-
mation or astrocyte development, leading to myelination defects
and astrocytic reaction. To address these issues, we deleted
Hdac3 alleles in developing neurons with a synapsin1-Cre
(Syn1-Cre) line, in which the neuron-specific Cre activity com-
mences at the early embryonic stage E12.5 (Zhu et al., 2001).
In Hdac3lox/lox;Syn1-Cre (CKO-Syn1) mice, we did not observe
drastic alterations in expression of the myelin gene Mbp, or
the astrocytic marker GFAP (Figures S3C and S3D) in the
brain and spinal cord at P14. In addition, to investigate the poten-
tial effects of Hdac3 deletion in the astrocyte lineage, we
bred Hdac3lox/lox with a mouse GFAP promoter-driven Cre line
(mGFAP-Cre), in which Cre selectively targets astrocytes
(Figure S4A) (Garcia et al., 2004). In the brain of Hdac3lox/lox;
mGFAP-Cre (CKO-mGFAP) mice, we did not detect substantial
changes in astrocyte formation and GFAP expression (Figure 3J)
or OL differentiation (Figure S4B). Together, these data suggest
that the effects of Hdac3 ablation on OL development are cell
autonomous and, among neural cells, restricted to the oligoden-
droglial lineage.
To further confirm that the ectopic astrocyte phenotype arose
during OL lineage specification in CKO-Olig1 mice, we crossed320 Developmental Cell 36, 316–330, February 8, 2016 ª2016 ElseviHdac3lox/lox mice with another early OL lineage-expressing Cre
line, Olig2-Cre (Ligon et al., 2007). Olig2-Cre-mediated Hdac3
deletion beginning at the primitive OPC stage, as in CKO-Olig1
mutants, yielded a substantial upregulation of expression of
cortical GFAP in the resultant Hdac3lox/lox;Olig2-Cre (CKO-
Olig2) mice (Figure 3K), as well as a myelination defect (Fig-
ure S4C). To explore this observation, we next assessed the
expression of S100b in Hdac3mutants, since this protein is nor-
mally expressed by both OPCs and astrocytes (Karram et al.,
2008). In the normal developing cortex, we found that S100b
was detected in a population of OPCs expressing Olig2, with
few cellular processes (Figure 3L). In the cortex of CKO-Olig2
mutants, we observed a loss of Olig2 expression in these cells,
which instead expressed robust S100b with extended bushy
cellular processes, and exhibited both astrocytic morphology
(Figure 3L) and GFAP expression (Figure 3M). These observa-
tions raised the possibility that Hdac3 ablation may cause a con-
version of OPCs to astrocytes.
Lineage Mapping Reveals that Hdac3 Ablation Diverts
OL Progenitors to an Astrocytic Fate
Given the reciprocal decrease in OPCs and increase in ectopic
astrocytes with Hdac3 ablation in Olig1+ or Olig2+ progenitors,
we hypothesized that Hdac3-deficient Olig+ pri-OPCs or OPCs
adopt an astrocytic fate when they fail to commit to the OL line-
age. To trace the cell fate of Hdac3-ablated cells, we bred CKO-
Olig1mice with Z/EG reporter mice (Zhu et al., 2012) (Figure 4A).
Cre-mediated loxP site excision simultaneously leads to Hdac3
deletion and activates EGFP expression. In the cortex of CKO-
Olig1;Z/EG at P14, essentially all EGFP-reporter+ cells ex-
pressed GFAP, in contrast to the control cortex (Figures 4B
and 4C). The majority of EGFP+ cells exhibited highly branched
bushy processes characteristic of protoplasmic astrocytes.
This suggests that cortical astrocytes with GFAP upregulation
or ectopically induced astrocytes were derived from Hdac3-ab-
lated Olig1+ progenitors.
To examine the fate of Hdac3-ablated OPCs in vitro, we car-
ried out Cre-mediated Hdac3 floxed allele excision in cultures
of purified PDGFRa+ OPCs. OPCs isolated from Hdac3lox/lox
pups were transduced with the lentivirus expressing GFP or
Cre-GFP. Three days post transduction, GFP-transduced
Hdac3lox/lox cells were maintained as Olig2+ OPCs while the
majority of Cre-GFP-transduced cells, in which Hdac3 expres-
sion was depleted, acquired GFAP expression and lost Olig2
expression (Figures 4D and 4E). Consistently, Hdac3 inhibition
by apicidin in purified OPCs elevated GFAP+ astrocyte formation
(Figures S5A and S5B) while causing a decrease in expression
of Olig2 and myelination-associated genes (Figure S5C).
To determine whether deletion of Hdac3 could convert OPCs
into astrocytes at the postnatal stage, we ablated Hdac3 in
OPCs by breeding tamoxifen (TAM)-inducible OPC-expressing
PDGFRa-CreERT2 (Rivers et al., 2008) and Rosa-tdTomato re-
porter lines with the floxed Hdac3 line to generate Hdac3lox/+
or Hdac3lox/lox;PDGFRa-CreERT2;Rosa-tdTomato mice, desig-
nated as Ctrl-PDGFRa and iCKO-PDGFRa, respectively. TAM
was administered into Ctrl- and iCKO-PDGFRa pups once daily
from P5 to P9, during the pre-myelinating stage. GFAP expres-
sion in the control and mutant brains harvested at P30 was
examined by immunostaining. In the corpus callosum, virtuallyer Inc.
Figure 3. Excessive Astrogliogenesis in the Hdac3 Mutant Brain
(A) The cortex of control and CKO-Olig1 mice at P14 and P67 was immunostained with GFAP. Arrows indicate the GFAP+ astrocytes.
(B–D) Expression of Glast mRNA, GS or GFAP, or MBP in control and CKO-Olig1 cortices at P14. Arrows indicate labeling cells. GAPDH was used as loading
control in (C).
(E) Quantification of the number of GS+ astrocytes in control and CKO-Olig1 cortices at indicated stages. n = 3 animals from each stage. *p < 0.05, Student’s
t test.
(F–H) The corpus callosum of control and CKO-Olig1mutants at P14 was immunostained with NFIA (F) and Sox10 (G). (H) shows the quantification of the number
of NFIA+ or Sox10+ cells/area (0.2 mm2) (n = 3 animals/genotype). Data are presented as mean ± SEM. *p < 0.05, Student’s t test.
(I) The cortex of CKO-Olig1 mice at P14 was immunostained with GFAP and Ki67 (arrow).
(J) GFAP and PDGFRa expression in cortices of control and Hdac3 CKO-mGFAP mice at P18.
(K) The cortex of control and CKO-Olig2 mice at P28 was immunostained with GFAP.
(L and M) The cortex of control and CKO-Olig2 mice at P28 was immunostained with Olig2 and S100b (L) and GFAP and S100b (M). Arrows indicate the co-
labeling cells.
Scale bars represent 100 mm (A, B, J, K) and 50 mm (D, F, G, I, L, M).
See also Figures S3 and S4.
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Figure 4. Hdac3 Ablation Leads to a Conver-
sion of OPCs to Astrocytes
(A) Diagram showing Cre-mediated EGFP expres-
sion in a Z/EG transgenic line.
(B and C) EGFP signals and GFAP+ cells in the
cortex of control Z/EG and CKO-Olig1;Z/EG mice.
The boxed area in (C) is shown on the right. Arrows
indicate a GFAP and EGFP co-labeled cell.
(D) OPC from Hdac3lox/lox pups were transduced
with lentiviral GFP or Cre-GFP and immunostained
with Hdac3 and GFP 3 days post infection. Arrows
indicate infected cells.
(E) Hdac3lox/lox OPCs were transduced with lenti-
viral GFP or Cre-GFP and immunostained with GFP
and Olig2 3 days post infection. Arrows indicate
infected cells.
Scale bars represent 50 mm (B–D) and 25 mm (E).
See also Figure S4.no GFAP+ cells were marked by tdTomato in Ctrl-PDGFRamice.
In contrast, we found that a population of tdTomato-labeled cells
became GFAP+ astrocytes (Figures 5A and 5C). Similarly, in the
cortex we observed a sizable fraction of tdTomato reporter-
labeled GS+ cells (22.8% ± 2.7%) in the Hdac3 mutants
compared with only a marginal fraction of these cells (3.1% ±
0.9%) in the control TAM-treated animals (Figures 5B and 5D).
To investigate whether Hdac3 deletion could alter the fate of
OPCs in adulthood, we next treated 5-week-old young adult
Ctrl- and iCKO-PDGFRa mutant mice with TAM for 10 days
(P35–P45) and harvested at P90. In these adults, we detected
a population of tdTomato reporter-labeled GFAP+ astrocytes in
the white matter of Hdac3 mutant mice, but not in control mice
(Figure 5C). Similarly, the percentage of reporter-expressing
GS+ astrocytes in the cortex was substantially higher in mutant
than control mice in adulthood, although the difference was
less marked than that noted at the early postnatal stage
(Figure 5D). Conversely, we detected a reduction of CC1+ OLs
among tdTomato+ cells in the TAM-induced Hdac3 mutants at
perinatal and adult stages (Figures 5E and 5F), suggesting that
ectopic formation of astrocytes is at the expense of OLs in
Hdac3 iCKO-PDGFRa mutants.
To further map the fate of OL progenitors in the absence of
Hdac3, we took advantage of the stable histone H2b-GFP in
CKO-Olig1mutant mice carrying the PDGFRa-H2bGFP knockin
reporter to trace the fate of OPCs. In these mutant mice, we
observed that a population of PDGFRa-H2bGFP+ cells, devoid
of the OL lineage marker Olig2, acquired astrocytic GFAP
expression in the cortex by P14 (Figure 5G). In contrast, no
GFAP+ cells were identified among PDGFRa-H2bGFP+ cells in
the control, suggesting that the ectopic astrocytes in the CKO-
Olig1 mutant cortex were derived from PDGFRa-expressing
OL precursors.
To determine the regional specificity of the astrocyte pheno-
type, we analyzed the optic nerve, a white matter tract in the
CNS, by immunostaining for the astrocyte markers Aldh1l1 and
GFAP. We observed a much stronger immunofluorescent signal322 Developmental Cell 36, 316–330, February 8, 2016 ª2016 Elsevier Inc.of Aldh1l1 or GFAP in the CKO-Olig1 mu-
tants than in the controls (Figures 5H and
S5D), with a concomitant loss of Olig2+
OLs, suggesting an increase of astrocytesin the optic nerve. Together, our data indicate that Hdac3 dele-
tion induces Olig1/2+ pri-OPCs and PDGFRa+ OPCs to adopt
an astrocytic fate in the CNS.
Hdac3Activates OL Lineagewhile Repressing Astrocyte
Lineage Transcriptional Programs
To define the Hdac3-regulated transcriptional program that
controls glial subtype development, we carried out RNA-seq
profiling analysis of the transcriptome between control and
CKO-Olig1 mutants using P12 optic nerves, which are highly
enriched with OLs and astrocytes. Gene ontology analysis of
differentially expressed genes demonstrated that significantly
downregulated genes in CKO-Olig1 mutants were correlated
with lipid biosynthesis and myelination (Figure S6A). Approxi-
mately 80% of OL-enriched genes in the neural cell type tran-
scriptome database (Cahoy et al., 2008; Zhang et al., 2014)
were downregulated in the CKO-Olig1mutants, including myelin
structural genes (e.g.Mbp, Plp1, and Cnp) and OL transcription
regulators (e.g. Sox10, Myrf/Gm98, Sip1/Zeb2, and Zfp191)
(Figures 6A and 6B). In contrast, upregulated genes in mutants
are associated with astrocyte-enriched genes, including GFAP,
Aqp9, Pla2g7, and Atp1a2 (Cahoy et al., 2008; Zhang et al.,
2014) (Figures 6A and 6B). The gene expression alterations are
consistent with OL myelination defects and an ectopic increase
of astrocytes in CKO-Olig1 mutant animals.
Genome Occupancy Analysis Reveals that Hdac3
Cooperates with p300 and Targets to Distinct Gene Loci
between OL and Astrocyte Lineages
To identify the direct target genes through which Hdac3
regulates oligodendroglial lineage development, we performed
chromatin-immunoprecipitation sequencing (ChIP-seq) analysis
for genome-wide chromatin occupancy by Hdac3 in OPCs and
maturing OLs (mOLs). Analysis of target loci revealed that
Hdac3 has both common and distinct genomic binding sites in
OPCs and mOLs (Figure 6C). The majority of Hdac3-targeting
sites were present in evolutionarily conserved intergenic regions,
Figure 5. Fate-Mapping Analyses Reveal
that the Ectopic Astrocytes Are Derived
from OPCs
(A and B) Ctrl-PDGFRa (Hdac3lox/+-PDGFRa-
CreERT2;tdT) and iCKO-PDGFRa (Hdac3lox/lox-
PDGFRa-CreERT2;tdT) mice were administered
with TAM from P5 to P9 for 5 days and harvested at
P30. Arrows indicate GFAP+ (A) or GS+ (B) astro-
cytes in Hdac3-ablated cells marked by tdTomato
expression.
(C–F) The percentage of GFAP+ (C), GS+ (D), or
CC1+ (E and F) cells among tdTomato+ cells in
Ctrl-PDGFRa and iCKO-PDGFRa mice with TAM
treatment from P5 to P9 and harvested at P30, and
TAM treatment from P35 to P45 and harvested at
P90 in the corpus callosum or cortex as indicated.
(G) The cortex of CKO-Olig1;PDGFRa-GFP mice at
P14 was immunostained with Olig2 and GFAP.
Arrows indicate GFAP+ H2bGFP+ Olig2- cells.
(H) The optic nerve of control and CKO-Olig1 mice
at P21 was immunostained with Olig2 and Aldh1l1
as indicated.
Data are presented as mean ± SEM in (C–F). At
least three animals from each stage were analyzed.
*p < 0.05, **p < 0.01, ***p < 0.001, Student’s t test.
Scale bars represent 25 mm (A, B, G) and 50 mm (H).
See also Figure S5.or introns of the gene loci (Figure S6B). Genetic loci targeted
uniquely by Hdac3 in mOL were enhancers linked to the genes
that are elevated during OL maturation (Figures 6D and S6C).
In contrast, in OPCs, a cohort of Hdac3-targeted sites was
distinct from those in mOL (Figure 6C). When compared with a
transcriptome database of neural cell types (Zhang et al.,
2014), Hdac3 targeting was situated within loci of the genes
that were mainly enriched in either OPCs or astrocytes (Fig-
ure 6E), which were downregulated or upregulated in CKO-
Olig1 mutants (Figures 6F and 6G), respectively.
Approximately 23%of Hdac3-binding sites in OPCs coincided
with the enhancer sites marked by the activating histone 3 K27
acetylation mark (H3k27ac) (Creyghton et al., 2010; Yu et al.,
2013) (Figure 6H). Since enhancer activities are often associated
with p300 histone acetyltransferase binding (Visel et al., 2009),
we analyzed p300 genomic occupancy in OPCs using ChIP-
seq. Strikingly, we found that these Hdac3-targeted enhancers
co-occupied by the transcriptional co-activator p300 were
OPC-enriched genes (Figure 6I), including Olig2, Cspg4/Ng2,
GPR17, and a chromatin remodeler Smarca2 (Figure 6J) (ZhangDevelopmental Cell 36, 316–330et al., 2014). Together with the downregu-
lation of these OPC-enriched genes in
Hdac3 mutants (Figure 6F), these obser-
vations suggested that Hdac3 cooperates
with p300 to target directly the enhancers
of OPC-expressing genes to activate their
expression.
In contrast, Hdac3-targeted regula-
tory elements with low or absent p300
were largely associated with astrocytes
including astrocyte-regulatory genes
such as NFIA (Figure 6K), a key factor in
astroglial specification (Glasgow et al.,2014), and astrocyte-associated genes including Aqp9, encod-
ing the water channel aquaporin 9, Gulp1, encoding engulfment
adaptor PTB domain containing 1 associated with phagocytosis
activity, P4ha2, prolyl 4-hydroxylase a2, and Gpam, encoding
mitochondrial glycerol-3-phosphate acyltransferase, all of which
are highly enriched in astrocytes (Figure 6L) (Zhang et al., 2014).
Given that their expression was upregulated in CKO-Olig1 mu-
tants (Figure 6G), this suggests that targeting by Hdac3 in the
absence of the p300 co-activator inhibits expression of NFIA
and other astrocyte-regulatory genes to block astrogliogenesis.
Hdac3 Inhibits Stat3 Acetylation to Antagonize
Jak-Stat3-Mediated Astrogliogenesis
Activation of the Jak-Stat signaling pathway has been shown to
promoteastrogliogenesis (Bonni et al., 1997;Heetal., 2005).Acet-
ylation of Stat3 at Lys685, a core downstream effector of the Jak-
Stat pathway, enhances Stat3 dimerization and its subsequent
phosphorylation to activate transcription (Becker et al., 1998;
Wang et al., 2005; Yuan et al., 2005). We then examined whether
Hdac3 could modulate post-translational modifications of Stat3, February 8, 2016 ª2016 Elsevier Inc. 323
Figure 6. Hdac3 Cooperates with p300 to Target Differentially on the Loci of OL and Astrocyte Lineage-Specific Genes
(A) RNA-Seq transcriptome profiling changes between control and CKO-Olig1 optic nerves. Representative transcripts of OL-enriched (red) or astrocyte-
enriched (blue) genes are shown.
(B) The percentage of annotated astrocyte- and OL-enriched genes based on the transcriptome database (Cahoy et al., 2008) among differentially expressed
transcripts.
(C) Heatmap of Hdac3-binding signals at OPCs and mOLs by ChIP-seq. The boxed areas using k-means clustering indicate unique Hdac3 binding loci in OPCs
and mOL, respectively.
(D) Temporal expression patterns of representative Hdac3-targeted genes in mOLwere plotted against differentiation stages from anOL transcriptome database
(Dugas et al., 2006).
(E) A pie chart shows that Hdac3 targeting sites in OPCs are associated with both astrocyte- and OPC-enriched genes. The others represent Hdac3 targets that
are not significantly enriched in OPCs or astrocytes based on the cell-type-specific transcriptome profiles (Cahoy et al., 2008).
(F and G) Heatmaps show expression patterns of representative OPC-enriched and astrocyte-enriched genes in the transcriptome of control and Hdac3
CKO-Olig1 optic nerves at P14 by RNA-seq.
(H) ChIP-seq enrichment shows binding profiles of H3k27ac around Hdac3 peak summits in OPC and mOL.
(I) ChIP-Seq enrichment analysis shows binding profiles of Hdac3 and p300 around H3k27ac peak summits in OPCs.
(J) The representative OPC-enriched gene loci that are targeted by Hdac3, p300, and H3k27ac marks (highlighted).
(K and L) The representative astrocyte-enriched gene loci that are targeted by Hdac3.
See also Figure S6.in Hdac3 mutants to regulate astrogliogenesis. In the corpus cal-
losum of both CKO-Olig1 and CKO-Olig2 mutants, we detected
a drastic increase in Stat3 acetylation (Ac-Stat3) compared with324 Developmental Cell 36, 316–330, February 8, 2016 ª2016 Elsevicontrol (Figure7A). Thephospho-Stat3 (P-Stat3Y705) level,which
is responsible for Stat3 nuclear translocation and DNA binding,
was also substantially increased (Figure 7A), suggesting a role ofer Inc.
Figure 7. Hdac3 Regulates Stat3 Signaling
Activity Post-transcriptionally to Inhibit
Astrogliogenesis
(A) Western blot analysis of the cortices from control
and Hdac3 mutants (CKO-Olig1 and CKO-Olig2) at
P68 with Stat3, acetyl-Stat3 (Ac-Stat3), phospho-
Stat3 (P-Stat3), and GAPDH.
(B) Western blot analysis of Stat3, P-Stat3, and
Ac-Stat3 in vehicle or apicidin-treated rat OPCs for
8 hr. GAPDH was used as a control.
(C) qRT-PCR analysis of CNTF and CT1 expression
from mRNAs isolated from the optic nerves of
control and CKO-Olig1 mutants at P21 (n = 3 ani-
mals; *p < 0.05, Student’s t test).
(D and E) The corpus callosum of the control and
CKO-Olig1 mice at P60 was immunostained with
Ac-Stat3, P-Stat3, and GFAP. Arrows indicate the
Ac-Stat3+ cells (D) or P-Stat3+ cells (E).
(F) The luciferase activity from the 293T cells
transfected with expression vectors harboring
Stat3, p300, or Hdac3 together with a GFAP
promoter-driven luciferase reporter after 48 hr.
*p < 0.05, **p < 0.01; ANOVA with Newman-
Keuls test.
(G and H) Co-immunoprecipitation with an antibody
to HA-tag p300 was carried out from 293T cells
transfected with HA-tag p300 together with Flag-
Stat3 and an increased amount of Flag-Hdac3 (H) or
Flag-Hdac1, 2, or 3 (H) after 48 hr. GAPDH was the
loading control.
(I) Rat astrocytes were transfected with the control,
Hdac3, and Hdac3-HEBI expressing vectors. Bar
graphs depict the relative expression of myelina-
tion-associated genes over control. *p < 0.05;
ANOVA with Newman-Keuls test.
(J) A proposed model for Hdac3 control of
OL-astrocyte fate switch. Hdac3 (ON) interacts with
p300 to activate Olig2 and promotes OL lineage
progression, while suppressing NFIA and Stat3
activity that otherwise sustains astrogliogenesis.
Hdac3 loss (OFF) results in an upregulation of astrogenic programs and a conversion of OL progenitors, including Olig1/2+ pri-OPCs and PDGFRa+ OPCs, into
astrocytes.
Data are presented as mean ± SEM from three independent experiments. Scale bars represent 50 mm (D, E).
See also Figure S7.Hdac3 for controlling the state of Stat3 post-translational modifi-
cations.We further detectedamoderate increaseofStat3, consis-
tentwith a positive feedback loopmechanismwhereby Stat3 acti-
vation induces the expression of Jak-Stat signaling components
andpromotesastrogliogenesis (Heetal., 2005). Inaddition,wede-
tected an upregulation of ciliary neurotrophic factor (CNTF) (Rajan
andMcKay, 1998) and cardiotrophin 1 (CT1) (Ochiai et al., 2001) in
the optic nerve ofHdac3mutants (Figure 7C). CNTFandCT1 have
been shown to activate Stat3 phosphorylation and subsequent
astrocytic differentiation through the CNTF/IL6-gp130 receptor-
Jak-Stat signaling pathway (Ochiai et al., 2001; Rajan andMcKay,
1998). Furthermore, treatment of an Hdac3/NcoR inhibitor apici-
din, but not Hdac1 orHdac8 inhibitors, in purifiedOPCs increased
P-Stat3 Y705 and acetylation levels (Figures 7B and S7A) while
promoting GFAP+ astrocyte formation (Figures S5A and S5B).
These data suggest that Hdac3 inhibition relieves the repression
of Stat3 acetylation or the Jak-Stat signaling pathway, permitting
redirection of OPCs to astrocytic fate.
To verify the activation of Stat3 in vivo,we immunostained con-
trol andHdac3mutantmice usingAc-Stat3- andP-Stat3-specificDevelopantibodies. Immunofluorescence of both Ac-Stat3 and P-Stat3
was dramatically upregulated in the corpus callosum of CKO-
Olig1 mutant brain (Figures 7D and 7E). Together with western
blot analysis, these observations suggest that Hdac3 ablation
leads to activation of the Stat3-mediated Jak-Stat pathway.
Hdac3 Competes with Stat3 for p300 Binding to
Suppress Astrocyte Phenotype
Stat3 was shown to activate the expression of astrocytic genes,
such asGFAP, and to promote astrogliogenesis through cooper-
ation with p300 (Nakashima et al., 1999). To determine the
possiblemechanismsofHdac3-driven inhibition of astrogliogene-
sis, we examined the effect of Hdac3 on GFAP promoter activity.
Co-expression of Stat3 and p300 transactivatedGFAP-luciferase
activity, while co-transfection of Hdac3 significantly blocked
Stat3/p300-activated reporter activity (Figure 7F). To determine
whether Hdac3 could compete with Stat3 for p300 binding and
disrupt the Stat3/p300 complex, we co-transfected expression
constructs carrying Stat3 and p300 as well as an increased
amount of Hdac3, and performed co-immunoprecipitation withmental Cell 36, 316–330, February 8, 2016 ª2016 Elsevier Inc. 325
anti-p300 on cell lysates 48 hr after transfection. Consistent with
previous studies (Nakashima et al., 1999), p300 was detected in
the same complex containing Stat3 in the absence of Hdac3.
However, in the presence of a low level of Hdac3, the amount of
Stat3 was reduced in the co-immunoprecipitated p300 com-
plex. With an increased level of Hdac3, essentially no Stat3 was
detected in the p300 complex (Figure 7G); instead, p300 and
Hdac3 were maintained in the complex (Figure 7G). These obser-
vationssuggest thatHdac3canhijackp300, effectively competing
with Stat3 to bind p300, and thereby inhibit astrogliogenesis.
Strikingly, co-immunoprecipitation assay indicated that Hdac3,
but not Hdac1 or Hdac2, interacts specifically with p300 (Fig-
ure 7H), suggesting that Hdac3 and p300 uniquely cooperate to
provide a fate switch between oligodendrogenesis and astroglio-
genesis. Furthermore, Hdac1/2 deletion by the Olig1-Cre line did
not cause a substantial increase in GFAP+ astrocytes, or in Stat3
modifications including acetylation and phosphorylation (Fig-
ure S7B). In addition, deletion of another class I HDAC, Hdac8,
with Olig1-Cre, did not appear to alter OL and GFAP+ astrocyte
development (Figure S7C). These data suggest a unique activity
for Hdac3 among HDAC family members in regulating astroglio-
genesis and Stat3 activity.
To assess the possibility that Hdac3 overexpression might
reprogram the transcriptional architecture of astrocytes, we
transfected purified astrocytes with control and Hdac3-overex-
pressing vectors. Hdac3 overexpression induced the expression
of OL-associated genes including Olig2, Sox10, Cgt, and Mag
(Figure 7I). In contrast, expression of an Hdac3 mutant form,
Hdac3-HEBI, which lacks deacetylase activity and is unable to
form a complex with NCoR/SMRT (Sun et al., 2013), did not
alter the expression of OL-associated genes (Figure 7I). These
observations suggest that Hdac3 activity is sufficient to activate
transcriptional programs characteristic of the OL lineage in
astrocytes.
DISCUSSION
Hdac3 Is a Cell-Intrinsic Epigenetic Switch for the Fate
Choice between OL and Astrocyte Lineages
The ability of OPCs to form OLs and type II astrocytes has been
well established in vitro (Raff et al., 1983). However, there is a
lack of convincing evidence showing that astrogliogenesis
from OPCs could actually occur in vivo during normal CNS
development (Kang et al., 2010; Rivers et al., 2008). This sug-
gests that cell-intrinsic genetic and/or epigenetic factors main-
tain and restrict OPC fate in vivo. Our lineage tracing studies,
using spatiotemporal lineage-specific Cre lines and fate map-
ping of PDGFRa-H2bGFP cells, suggest that the loss of Hdac3
led to themisdirection of OL progenitors to the astrocyte lineage.
This effect was likely cell autonomous, because a substantial
increase of astrocytes was observed when Hdac3 was deleted
in the Olig1/2+ pri-OPCs or OPCs, but not when it was deleted
from GFAP+ astrocytes, or from neurons during early postnatal
development. These findings demonstrate that the chromatin-
modifying enzyme Hdac3 is critical for OPC specification and
phenotypic maintenance, and epigenetically governs oligoden-
drocyte and astrocyte fate decision.
Type II astrocytes have been defined as astrocytes derived
from OPCs, while type I astrocytes arise from multipotent neural326 Developmental Cell 36, 316–330, February 8, 2016 ª2016 Elseviprogenitor cells, but not from OPCs. We observe that a popula-
tion of GFAP+ astrocytes is derived from pri-OPCs, OPCs, and
PDGFRa-H2bGFP-expressing OPCs in Hdac3 mutants. Hence,
we provide in vivo evidence that GFAP astrocytes can be derived
from OPCs in the absence of Hdac3, and resemble the type II
astrocytes.
While class I HDACs have been shown to be involved in neural
stem/progenitor cell development (Jiang and Hsieh, 2014; Mont-
gomery et al., 2009; Norwood et al., 2014), the present study
reveals a distinct role of Hdac3 in glial subtype switching, and
in establishment and maintenance of OL identity. This fate-
switch mechanism is unique to Hdac3, as knockouts of Hdac1,
Hdac2, or both together, or Hdac8, do not alter OPC fate or
induce astrogliogenesis. Thus, the essential role of Hdac3 in
OL-astrocyte fate switch is not shared by other HDACs. Our
finding, which implicates a specific HDAC as a regulatory
determinant at a well-defined developmental crossroad,
challenges previous assumptions relegating class I HDACs to
generic cellular machinery or veritable housekeepers involved
in chromatin compaction.
Recent studies indicate that Olig2 is a critical regulator of
developmental switch between NG2-expressing OPCs and
astrocytes (Zhu et al., 2012), and functions as a negative regu-
lator of the astrocytic differentiation pathway (Fukuda et al.,
2004). We find that Hdac3 activates and maintains Olig2, which
triggers expression of a downstreamOL-promoting factor Sox10
(Yu et al., 2013), and primes the progenitor fate toward OL line-
age. In addition, we show that Hdac3 can target directly and
inhibit the expression of NFIA (Figures 6G and 6K), which is a
key transcription factor in the specification of astroglial identity
and differentiation (Glasgow et al., 2014). Thus, our data demon-
strate that Hdac3 controls the OL-astrocyte fate switch not only
by activating an OL specification factor, Olig2, but also by sup-
pressing expression of the key astroglial regulator NFIA and
Stat3 activity that otherwise sustains astrogliogenesis. Collec-
tively, these data suggest that Hdac3 acts upstream in the regu-
latory network (Figure 7J) to control phenotypic commitment of
OL and astrocyte lineages.
Control of OL-Astrocyte Lineage Commitment by
Coordinate Interaction of HDAC and HAT
Inhibition of class I HDAC activity results in a defect in OL differ-
entiation (Marin-Husstege et al., 2002; Ye et al., 2009), yet both
genetic and RNA knockdown of the HAT Cbp/p300 also lead
to decreased expression of OL genes and the inhibition of mye-
lination (Wang et al., 2010). This suggests that both HDAC and
HAT activities are required for proper OL development.
How does Hdac3 achieve cell-type-specific functions to regu-
late OL versus astrocyte lineage? Our data suggest that Hdac3
targets the regulatory regions of OPC-associated and astro-
cyte-enriched genes in a distinct fashion. Strikingly, Hdac3
appears to coordinate with a co-activator, p300, to target the
enhancers of OPC-enriched genes and promote their expres-
sion, while Hdac3 targets the loci of astrocyte-enriched genes
in the absence of p300, repressing their expression. Given
the potential transcriptional repressive function of the Hdac3/
NCoR complex (You et al., 2013), the cooperation of Hdac3
with distinct partners such as p300 or NCoR likely controls the
selected expression of downstream targets, with the presenceer Inc.
of p300 as an activating mark for OL lineage progression.
Concurrently, Hdac3 can hijack p300 from the Stat3 complex
to inhibit Stat3-mediated astrocytic gene expression (Figure 7J).
Hdac3 has been shown to form a complex with the NCoR1 or
SMRT/NcoR2 for its repressive activity (Guenther et al., 2001).
NCoR1 suppresses cytokine-induced astrocyte differentiation
and inhibits astrocyte lineage-specific gene expression (Her-
manson et al., 2002; Sardi et al., 2006). Since NCoR1 can be
stably associated with Hdac3 (Guenther et al., 2001), Hdac3/
NCoR1 likely acts as a co-repressor complex to repress astro-
cytic gene expression (Figure 7J). Hence, Hdac3 may possess
diverse functions through interacting with distinct co-regulators
to refine the chromatin landscape, and thereby establish a spe-
cific transcriptional program for OL lineage commitment while
suppressing astrocytic fate.
Hdac3 Regulates Jak-Stat3 Activity Post-translationally
to Suppress Astrogliogenesis
Besides regulating gene expression, Hdac3 also attenuates the
activity of astrogliogenic factors through post-translational
modifications. In particular, we find that Hdac3 can deacetylate
Stat3, and thereby repress Stat3 activity for astrogliogenesis.
Stat3 acetylation is critical for Stat3 dimerization, phosphoryla-
tion, and nuclear translocation (Yuan et al., 2005), leading to
the activation of downstream transcriptional events. The exact
mechanisms underlying the regulation of Stat3 hyperphosphor-
ylation remain to be determined. It is possible that the increase
in acetylation of Stat3 in Hdac3 mutants facilitates Jak to phos-
phorylate Stat3 to promote an astrocytic fate. Alternatively,
Hdac3 loss could lead to the activation of Jak-Stat3 signaling
indirectly by elevating astrogliogenesis-inducing cues such as
CNTF and CT1 (Figure 7C). These observations suggest that
Hdac3 negatively regulates the Jak-Stat3 signaling pathway to
block astrocytic differentiation.
Hdac3 appears to exert its function through both histone
deacetylase-dependent and deacetylase-independent mecha-
nisms (Sun et al., 2013). For histone deacetylase-independent
functions, Hdac3 may act as a platform to maintain the integrity
of co-repressor complexes or to modify the activity of other
transcriptional machinery (Alenghat et al., 2006; Sun et al.,
2013). NCoR1 and SMRT consist of histone deacetylase activa-
tion domains (DAD) that enhance Hdac3 histone deacetylase
activity. Intriguingly, we find that the deletion of DAD domains
of both NCoR1 and SMRT in mutant mice (NS-DADm), which
lack histone deacetylase activity in the NCoR/Hdac3 complex
(You et al., 2013), does not lead to an OL-astrocyte fate
switch and elevation of Stat3 acetylation and astrogliogenesis
(Figure S7D). This suggests a unique role of Hdac3 in Stat3
post-transcriptional modification. Thus, Hdac3 may function
independently of NCoR1/SMRT-mediated histone deacetylase
activity, and Hdac3 activity per se or Hdac3/NCoR-mediated
transcriptional regulation is required for controlling OL-astrocyte
fate switching.
Our data indicate that Hdac3 modulates the fate switch by
controlling expression of OL specification gene Olig2 at the
pivotal point of the OL versus astrocyte fate decision. Hdac3
further inhibits activation of Jak-Stat3 activity, which promotes
the commitment to an astrocytic fate and astrogliogenesis.
These tandem activities of Hdac3 provide it a unique positionDevelopfrom which to control the acquisition of glial phenotype, by
silencing lineage-inappropriate genes and signaling pathways
to ensure that OL identity is heritably maintained. Together, our
studies demonstrate that Hdac3 regulates an OL-to-astrocyte
fate switch through two levels of mechanisms: firstly by interact-
ing with p300 to activate Olig2 expression while inhibiting NFIA
transcriptionally during early fate specification, and secondly
by blocking JAK/Stat3 activity at a post-transcriptional level
that otherwise promotes astrocytic differentiation.
Hdac3 in Demyelinating Diseases and CNS Injury
Fate-switch control is clinically significant, since a misguided
fate switch of OPCs into astrocytes may cause depletion of
OPC pools, leading to remyelination failure in MS lesions, which
are typically pervaded by a dense astroglial milieu (Kotter et al.,
2011). We observe a strong upregulation of Hdac3 expression in
the lesion penumbra following lysolecithin-mediated demyelin-
ation (Figure S7E), suggesting a potential role of Hdac3 in regu-
lating OL regeneration, although Hdac3 function in remyelination
remains to be determined. Inflammatory lesions in particular
would be expected to raise cytokines that stimulate the Jak-
Stat pathway to promote astrogliosis and glial scar formation
at the expense of OLs, thus impeding myelin repair (Burda and
Sofroniew, 2014; Gallo and Deneen, 2014). The induction of
Hdac3 might permit the dynamic reversal of astrocytic fate and
reacquisition of oligodendrocytic competence. In addition, our
finding of the p300 function in OL fate specification has an impli-
cation on the pathogenesis of Rubinstein-Taybi syndrome. A
type 2 form of the disease caused by a loss-of-function mutation
in EP300 (p300) manifests, along with other systemic abnormal-
ities, hypoplasia of the corpus callosum, reflecting congenital
hypomyelination (Solomon et al., 2015). Given this critical role
for Hdac3/p300 as a proximal regulator of the OL-astrocyte
fate switch, it is conceivable that enhancing Hdac3/p300 inter-
action or activity might promote or maintain OL identity while
reprogramming astrocytes for OL regeneration. This capability
would have broad and important applicability, both in vitro as a
means of potentiating and accelerating the production of myeli-
nogenic OPCs from pluripotential stem cells, and in vivo as a
means of directing therapeutically meaningful remyelination by
parenchymal progenitors otherwise fated to gliosis.
EXPERIMENTAL PROCEDURES
Full details are provided in the Supplemental Experimental Procedures. Com-
plete protocols are available upon request from richard.lu@cchmc.org.
Animals and Experiments
Hdac3lox/lox (Montgomery et al., 2008) and Hdac8lox/lox mice (Haberland et al.,
2009a) were from Dr. Eric Olson. Olig2-Cre (stock no. 011103), Syn1-Cre
(stock no. 003966), and mGFAP-Cre mouse line 77.6 (stock no. 024098)
were from The Jackson Laboratory. PDGFRa-CreERT2 line (Rivers et al.,
2008) was from Dr. W.D. Richardson. NS-DADm mice carrying deacetylase-
activating domain mutations in NCoR1 and SMRT were previously described
(You et al., 2013). Phenotypic analyses were performed blindly without prior
knowledge of animal genotypes. We used both male and female mice on a
mixed C57Bl/6; 129Sv; CD-1 background, unless otherwise specified. Immu-
nohistochemistry of tissue and electron microscopy were performed using
standard methods. All animal use and studies were approved by the Institu-
tional Animal Care and Use Committee of Cincinnati Children’s Hospital
Medical Center.mental Cell 36, 316–330, February 8, 2016 ª2016 Elsevier Inc. 327
Primary Cell Culture and Transfection
Primary rat OPCs and astrocyte cultures have been described previously
(Chen et al., 2007). Mouse OPCs were purified from transgenic mice by immu-
nopanning as described by Chan et al. (2004). Rat OPCs or astrocytes were
transfected with expression vectors using Amaxa Nucleofector (Lonza)
according to the manufacturer’s protocol. The detailed information for stan-
dard cell culture, immunocytochemistry, qRT-PCR, and western blotting and
co-immunoprecipitation assays are described in Supplemental Experimental
Procedures.
ChIP-Seq, Peak Calling, and Data Analysis
ChIP-seq assays were performed in the nuclei isolated from OPCs and mOL
(3 days after T3 treatment of OPCs) (20 million cells) using the antibodies
Anti-Hdac3 (Abcam ab7030), p300 (Santa Cruz sc-585), Olig2 (Millipore
AB9610), and Histone 3 Ac-K27 (Active Motif 39133), as previously described
with minor modifications (Yu et al., 2013); for details see Supplemental Exper-
imental Procedures. All sequencing data were mapped to rat genome assem-
bly version rn5 and peak calling was performed using MACS (Model-based
Analysis of ChIP-Seq) version 1.4.2 (http://liulab.dfci.harvard.edu/MACS)
with default parameters to obtain primary binding regions. These primary
peak regions were further filtered using the following criteria to define a
more stringent protein-DNA interactome: (1) the p-value cutoff was set
to <105; (2) an enrichment of 5-fold.
RNA-Seq and Data Analysis
RNAs isolated from the optic nerves of control mice andHdac3mutants at P12
were subject to RNA-seq using an Illumina HiSeq 2500 system. RNA-seq
reads were mapped using TopHat with default settings. TopHat output data
were then analyzed by Cufflinks to (1) calculate FPKM values (fragments per
kilobase of exon fragments mapped) for known transcripts in mouse genome
reference, and (2) test for significant changes of gene expression between
control and mutant tissues.
Lysolecithin-Induced Injury
Lysolecithin-induced demyelination was carried out in the spinal cord of
8-week-old mice as detailed in Supplemental Experimental Procedures. In
brief, 0.5 ml of 1% lysolecithin (Sigma L4129) via a Hamilton syringe attached
to a glass micropipette was injected into the ventrolateral white matter via a
stereotactic apparatus.
Statistical Analysis
All analyses were carried out usingMicrosoft Excel or PrismGraphPad 6.00 for
Mac OS (http://www.graphpad.com/). Quantifications were performed from at
least three independent experimental groups. Data are presented as mean ±
SEM in the graphs. p Values are from Student’s two-tailed t test to compare
two sets of data. To compare more than two sets, we conducted one-way
ANOVA analysis with a Newman-Keuls multiple comparison test for post
hoc analysis. p < 0.05 is considered to be statistically significant.
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